2nd Quarter - Report

AKIN GUMP STRAUSS HAUER & FELD for BIOTECHNOLOGY INNOVATION ORGANIZATION

Firm
Client
Income
$70,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to the reauthorization of the FDA user fee agreements and pandemics bill; issues related to FDA user fee agreements (S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act) and H.R. 7667, Food and Drug Amendments of 2022); issues related to prescription drug importation.

LobbyistCovered position, as disclosed
ANNA ABRAM —
MICHAEL BARNARD —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 7667 (117th), S. 4348 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.